Leap Therapeutics Inc to Post Q2 2020 Earnings of ($0.25) Per Share, Piper Sandler Forecasts (NASDAQ:LPTX)

Share on StockTwits

Leap Therapeutics Inc (NASDAQ:LPTX) – Stock analysts at Piper Sandler issued their Q2 2020 earnings estimates for Leap Therapeutics in a research note issued on Monday, June 29th. Piper Sandler analyst T. Van. Buren forecasts that the company will earn ($0.25) per share for the quarter. Piper Sandler currently has a “Overweight” rating and a $6.00 price target on the stock. Piper Sandler also issued estimates for Leap Therapeutics’ Q3 2020 earnings at ($0.15) EPS, Q4 2020 earnings at ($0.20) EPS, FY2020 earnings at ($1.00) EPS, Q1 2021 earnings at ($0.15) EPS, Q2 2021 earnings at ($0.20) EPS, Q3 2021 earnings at ($0.20) EPS, Q4 2021 earnings at ($0.20) EPS, FY2021 earnings at ($0.75) EPS, FY2022 earnings at ($0.95) EPS, FY2023 earnings at ($1.15) EPS and FY2024 earnings at ($1.55) EPS.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.31). The business had revenue of $0.38 million for the quarter.

LPTX has been the topic of several other reports. Zacks Investment Research lowered shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Raymond James set a $2.50 target price on shares of Leap Therapeutics and gave the company an “outperform” rating in a research report on Friday, June 12th. HC Wainwright reiterated a “buy” rating and set a $5.00 target price (up from $2.50) on shares of Leap Therapeutics in a research report on Tuesday, May 19th. Finally, ValuEngine upgraded shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, May 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $4.15.

NASDAQ LPTX opened at $2.18 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.82 and a current ratio of 2.82. The company’s fifty day moving average is $2.32 and its two-hundred day moving average is $1.92. Leap Therapeutics has a 52-week low of $0.57 and a 52-week high of $3.18.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Leap Therapeutics by 21.5% during the 1st quarter. BlackRock Inc. now owns 38,946 shares of the company’s stock valued at $62,000 after purchasing an additional 6,897 shares during the last quarter. Personal CFO Solutions LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $101,000. Perceptive Advisors LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $10,627,000. Gratus Capital LLC bought a new position in Leap Therapeutics during the 1st quarter valued at about $40,000. Finally, Sphera Funds Management LTD. bought a new position in shares of Leap Therapeutics in the first quarter worth about $948,000. 31.38% of the stock is owned by hedge funds and other institutional investors.

In other news, major shareholder Perceptive Advisors Llc purchased 1,750,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $2.00 per share, with a total value of $3,500,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 25.89% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Featured Story: What is a dead cat bounce?

Earnings History and Estimates for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

16,081 Shares in Applied Materials, Inc.  Acquired by Mount Yale Investment Advisors LLC
16,081 Shares in Applied Materials, Inc. Acquired by Mount Yale Investment Advisors LLC
Diligent Investors LLC Buys New Stake in Marsh & McLennan Companies, Inc.
Diligent Investors LLC Buys New Stake in Marsh & McLennan Companies, Inc.
455 Shares in Netflix, Inc.  Acquired by Diligent Investors LLC
455 Shares in Netflix, Inc. Acquired by Diligent Investors LLC
IBM Retirement Fund Sells 270 Shares of State Street Corp
IBM Retirement Fund Sells 270 Shares of State Street Corp
Carnegie Capital Asset Management LLC Purchases 4,761 Shares of PNC Financial Services Group Inc
Carnegie Capital Asset Management LLC Purchases 4,761 Shares of PNC Financial Services Group Inc
Webster Bank N. A. Invests $61,000 in Southwest Airlines Co
Webster Bank N. A. Invests $61,000 in Southwest Airlines Co


 
© 2006-2020 Zolmax.